Similar Search Results

An optimization model for distribution of influenza vaccines through a green healthcare supply chain

Levner, Ilya; Herbon, Avi - In: Operations research for health care 37 (2023), pp. 1-15

Persistent link: https://www.econbiz.de/10014310102

Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany

Damm, Oliver; Eichner, Martin; Rose, Markus Andreas; … - In: The European journal of health economics : HEPAC ; … 16 (2015) 5, pp. 471-488

Persistent link: https://www.econbiz.de/10011299236

Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses

García-Ruiz, Antonio J.; Pérez-Costillas, Lucía; … - In: Health economics review 2 (2012) 8, pp. 1-12

Background: Schizophrenia is a severe form of mental illness which is associated with significant and long-lasting health, social and financial burdens. The aim of this project is to assess the efficiency of the antipsychotics used in Spain in reducing schizophrenia relapses under the Spanish...

Persistent link: https://www.econbiz.de/10009621773

The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997 - 2010 : evidence from longitudinal, disease-level data

Lichtenberg, Frank R.; Pettersson, Billie - In: Economics of innovation and new technology 23 (2014) 3/4, pp. 239-273

Persistent link: https://www.econbiz.de/10010407486

Value-based clinical trials : selecting recruitment rates and trial lengths in different regulatory contexts

Alban, Andres; Chick, Stephen E.; Foster, Martin - 2021

Persistent link: https://www.econbiz.de/10012631361

Cost-effectiveness analysis of vaborem for the treatment of carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections in the UK

Vlachaki, Ioanna; Zinzi, Daniela; Falla, Edel; … - In: The European journal of health economics 23 (2022) 3, pp. 537-549

Persistent link: https://www.econbiz.de/10013198220

Stratified medicine in schizophrenia : how accurate would a test of drug response need to be to achieve cost-effective improvements in quality of life?

Jin, Huajie; McCrone, Paul; MacCabe, James H. - In: The European journal of health economics : HEPAC ; … 20 (2019) 9, pp. 1425-1435

Persistent link: https://www.econbiz.de/10012221385

Economic evaluation of meningococcal vaccines : considerations for the future

Christensen, Hannah; Al-Janabi, Hareth; Lévy, Pierre; … - In: The European journal of health economics : HEPAC ; … 21 (2020) 2, pp. 297-309

Persistent link: https://www.econbiz.de/10012221975

Are biopharmaceutical budget caps good public policy?

Goldman, Dana P.; Lakdawalla, Darius; Baumgardner, James R. - In: The Economists' voice 13 (2016) 1, pp. 27-42

Persistent link: https://www.econbiz.de/10011585711

A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer

Nguyen Cuc Thi Thu; Petrelli, Fabio; Scuri, Stefania; … - In: The European journal of health economics : HEPAC ; … 20 (2019) 5, pp. 763-777

Persistent link: https://www.econbiz.de/10012061274